Cargando…

Nivolumab-Induced Organizing Pneumonia in Management of Non-small Cell Lung Carcinoma: A Case Report

Nivolumab is an immune checkpoint inhibitor (ICI) that has proven efficacy in managing certain malignancies, including non-small lung carcinoma. In this case, we present a 53-year-old female patient diagnosed with metastatic non-small lung carcinoma. After management with radiation (both external be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Habib, Tehmina, Abu-Abaa, Mohammad, Kolman-Taddeo, Diana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276897/ https://www.ncbi.nlm.nih.gov/pubmed/37337505 http://dx.doi.org/10.7759/cureus.39217

Ejemplares similares

Report of a Rare Case of Intracranial Extramedullary Hematopoiesis Mimicking a Brain Tumor
por: Habib, Tehmina, et al.
Publicado: (2023)

A Case of Advanced Multifocal Cholangiocarcinoma With Excellent Response to Pembrolizumab
por: Habib, Tehmina, et al.
Publicado: (2023)

Cushing's Disease Associated With Partially Empty Sella Turcica Syndrome: A Case Report
por: Habib, Tehmina, et al.
Publicado: (2023)

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Yang, Szu-Chun, et al.
Publicado: (2021)

A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer
por: Liu, Chang, et al.
Publicado: (2021)

Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review
por: van Eeden, Ronwyn, et al.
Publicado: (2019)

Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy
por: Jiang, Meilin, et al.
Publicado: (2020)

Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer
por: Aiello, Marco Maria, et al.
Publicado: (2020)

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers
por: Daher, Sameh, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
por: Hu, Huabin, et al.
Publicado: (2020)

Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report
por: Arias Ron, David, et al.
Publicado: (2019)

An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer
por: Jiang, Panpan, et al.
Publicado: (2021)

Case Report: Pseudoprogression With Nivolumab and Bevacizumab Followed by Recurrent Immune-Related Pneumonitis in Urothelial Carcinoma With Lung Metastasis
por: Yang, Zizhong, et al.
Publicado: (2021)

Immunocheckpoint Inhibitor- (Nivolumab-) Associated Hypereosinophilia in Non-Small-Cell Lung Carcinoma
por: Singh, Navdeep, et al.
Publicado: (2020)

Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study
por: Awad, Mark M., et al.
Publicado: (2021)

Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study
por: Egami, Saeka, et al.
Publicado: (2021)

Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study
por: Ogiwara, Toshiki, et al.
Publicado: (2021)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma
por: Charles, Rebecca, et al.
Publicado: (2023)

Nivolumab in Metastatic Non–Small Cell Lung Cancer
por: Deel, Andrea
Publicado: (2016)

Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer
por: Goldman, Jonathan W., et al.
Publicado: (2019)

Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study
por: Awad, Mark M., et al.
Publicado: (2022)

The Management of Brain Metastases in Non-Small Cell Lung Cancer
por: Owen, Scott, et al.
Publicado: (2014)

Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management
por: Yanase, Takahiro, et al.
Publicado: (2020)

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
por: George, Daniel J, et al.
Publicado: (2022)

Isolated penile ulceration after Nivolumab therapy for non-small cell lung carcinoma
por: Baaklini, Gina T., et al.
Publicado: (2020)

Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy
por: Nishimura, Tomoka, et al.
Publicado: (2022)

Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist’s Perspective
por: Brega, Elisa, et al.
Publicado: (2014)

The Complete Response of a Renal Cell Carcinoma Metastatic to Brain, Lungs, and Liver to Second-Line Nivolumab: A Case Report
por: Haghpanah, Mahsa, et al.
Publicado: (2022)

Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy
por: Schwab, Katjana S., et al.
Publicado: (2019)

Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer
por: Turkaj, Ana, et al.
Publicado: (2018)

Surgical Management of Stage IIIA Non-Small Cell Lung Cancer
por: Van Schil, Paul E., et al.
Publicado: (2017)

Nivolumab and Hypofractionated Radiotherapy in Patients With Advanced Lung Cancer: ABSCOPAL-1 Clinical Trial
por: Ye, Hua, et al.
Publicado: (2021)

Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP)
por: Ishiwata, Tsukasa, et al.
Publicado: (2017)

Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma
por: Hata, Shinro, et al.
Publicado: (2020)

Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma
por: Katsuya, Yuki, et al.
Publicado: (2023)

Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases
por: Liu, Hao, et al.
Publicado: (2022)

Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy
por: Donaldson, Marie, et al.
Publicado: (2018)

The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer
por: Crombet Ramos, Tania, et al.
Publicado: (2021)

Concurrent use of nivolumab and radiotherapy for patients with metastatic non-small cell lung cancer and renal cell carcinoma with oligometastatic disease progression on nivolumab
por: Ansari, Jawaher, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kl4877khvfp54hlocao4q0rgp9